The roles of circulating renin-angiotensin-aldosterone system in human pregnancy

Eugenie R. Lumbers and Kirsty G. Pringle

School of Biomedical Sciences and Pharmacy and Mothers and Babies Research Centre, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, Australia, 2308.

Running Title: The circulating renin-angiotensin system in pregnancy

Address for correspondence: Emeritus Scientia Professor Eugenie R. Lumbers, School of Biomedical Sciences, University of Newcastle, Callaghan, Newcastle, NSW Australia, 2308.

Eugenie.Lumbers@newcastle.edu.au

Key Words: renin-angiotensin-aldosterone system, pregnancy, fluid and electrolyte balance, renal function, circulation
Abstract
This review describes the changes that occur in circulating renin-angiotensin-
alosterone (RAAS) system components in human pregnancy. These changes
depend on endocrine secretions from the ovary and possibly the placenta and
decidua. Not only do these hormonal secretions directly contribute to the increase in
RAAS levels, they also cause physiological changes within the cardiovascular system
and the kidney, which in turn induce reflex release of renal renin. High levels of Ang
II play a critical role in maintaining circulating blood volume, blood pressure and
uteroplacental blood flow through interactions with the Ang II type I receptor, and
through increased production of downstream peptides acting on a changing Ang
receptor phenotype. The increase in Ang II early in gestation is driven by estrogen-
induced increments in angiotensinogen (AGT) levels, so there cannot be negative
feedback leading to reduced Ang II production. AGT can exist in various forms in
terms of redox state or complexed with other proteins as polymers; these affect the
ability of renin to cleave Ang I from AGT. Thus during pregnancy the rate of Ang I
production varies not only because levels of renin change in response to
homeostatic demand but also because AGT changes not only in concentration but in
form. Activation of the circulating and intrarenal RAASs is essential for normal
pregnancy outcome subserving the increased demand for salt and hence water
during pregnancy. Thus the complex integration of the secretions and actions of the
circulating maternal renin-angiotensin system in pregnancy plays a key role in
pregnancy outcome.

Introduction
In human pregnancy, the maternal and fetal circulating renin-angiotensin-
alosterone systems (RAAS) and various tissue renin-angiotensin systems (RAS)
interact to ensure a satisfactory pregnancy outcome. Tissue RASs critically involved
in normal pregnancy are the ovarian, intrauterine (placental and decidual) and the
intrarenal RASs. The non-renal RASs not only play key roles in ovulation,
implantation, placentation and development of the uteroplacental and
umbilicoplacental circulations but they contribute to the activity of the circulating
maternal RAAS, so influencing maternal cardiovascular and renal function. The role
of the maternal circulating RAAS is the topic of this review. It should be appreciated that the fetus also has a circulating functional renin-angiotensin system, and this system together with its intrarenal RAS is essential for normal renal development and function (33, 81).

The activity of the maternal circulating RAAS in pregnancy does not solely depend on release of active renin from the kidney. Although this source of renin is important, increased production of angiotensinogen by the liver is also a major influence. Its activity is also influenced at various stages of gestation by contributions from the ovary and uteroplacental unit. The actions of the maternal circulating RAAS are mediated through various Ang peptides and receptors (see Figure 1). Angiotensin II (Ang II) acting via the Ang II type 1 receptor (AT1R) is predominantly vasoconstrictor; it is also a major regulator of aldosterone secretion. There are additional actions of Ang II mediated via an AT2R and of other Ang peptides, in particular, Ang 1-7 via the Mas receptor and Ang IV via AT4R. Ang IV can however also act via AT1aR in the mouse kidney (88). These other Ang peptides, which are also part of the circulating RAAS, and their actions, are also likely to contribute to pregnancy outcome.

This review describes our current understanding of the circulating RAAS, how it changes during normal pregnancy and how it contributes to changes in cardiovascular and renal function in order to maintain fluid and electrolyte balance and tissue perfusion.

The circulating RAAS

The circulating RAAS is defined by the action of renin, a 36 kDa aspartyl protease, that cleaves a Val-Leu bond in a large 62 kDa α2-globulin substrate, angiotensinogen (AGT), to form angiotensin I (Ang I). Ang I is converted to Ang II by angiotensin converting enzyme (ACE). Ang II is the major Ang peptide; its most well described biological actions are mediated via the AT1R, (Figure 1(a)). Other Ang peptides in the circulation include Ang (1-7), which is formed at the fastest rate from Ang II (15, 64) and Ang III and Ang IV (Figure 1(b), (3, 15)).
Ang II, as well as acting via its AT₁R, can also bind to the Type 2 receptor (AT₂R). Many actions of the Ang II/AT₂R interaction oppose the actions of Ang II/AT₁R. Briefly, Ang II/AT₁R interactions cause vasoconstriction, aldosterone synthesis and secretion, angiogenesis and proliferation. Those mediated by Ang II/AT₂R include vasodilatation and apoptosis (15). Ang (1-7) acts via the MasR, a G protein coupled receptor (64) and many of its actions oppose the Ang II/AT₁R induced effects as do the actions of Ang IV mediated via the AT₄R also known as IRAP (insulin regulated aminopeptidase (3)). Ang IV/IRAP induced effects include hypertrophy, vascularisation, inflammation and vasodilation (10) as well as actions mediated via AT₁Rs (88). IRAP has been shown to be identical to placent al oxytocinase (45).

The discovery of a precursor of active renin (now called prorenin) many years ago (32) was initially regarded as of little biological significance because prorenin, which has a 28 amino acid prosequence that covers its catalytic site, was thought to be biologically inactive. It could be shown to be activated in vitro by low pH (32), cold and proteases such as trypsin (44) and cathepsin D (43). Even today the biological significance of "in vivo" proteolytic activation of prorenin, remains obscure except for the specific proteolysis that occurs within the juxtaglomerular cells lining the afferent arterioles of the kidney that results in storage and release of active renin from these cells into the blood.

In 2002 the biological significance of prorenin was realised following the discovery of a prorenin receptor ((P)RR). The 45 kDa protein cloned by Nguyen et al. (49) is, in part, identical to a 8.9 kDa truncated protein ‘M8-9’ that is co-purified with a vacuolar proton-ATPase (V-ATPase). (P)RR binds prorenin so that its catalytic site is exposed and Ang I can be cleaved from AGT (49). There are three pathways via which prorenin bound to (P)RR can have biological effects: first by cleavage of Ang I from AGT, second by activation of intracellular signalling (phosphorylation of ERK1/ERK2 or by activation p27/HSP pathway (49, 66)) and third, through the interaction of (P)RR with Wnt signalling pathways (48). The fact that (P)RR knockouts are embryo lethal, indicates that (P)RR plays an essential role in normal development.
A soluble form of (P)RR, (s(P)RR), has also been described. It is the 28 kDa portion of the receptor that is cleaved from the M8-9 component by the enzyme furin (48) and is found in the circulation. Thus circulating prorenin, which is much more abundant in the blood than active renin and which increases to very high levels early in pregnancy (Figure 2(a)) is no longer confined to the role of an inactive precursor of active renin. It has its own biological activity, possibly as a circulating hormone. s(P)RR may also be important in influencing the rate of formation of Ang I from AGT in plasma and other bodily fluids (see below, (89)).

Changes in components of the circulating RAAS in normal pregnancy

Angiotensinogen (AGT)

As stated above the activity of the circulating renin angiotensin system depends upon both the amount of renin capable of interacting with AGT and the amount of AGT. Plasma renin activity is a measure of the angiotensin forming capacity of plasma. AGT production parallels that of estrogen, the correlation coefficient for AGT and estradiol-17β is 0.60 and for AGT and estriol is 0.68 (25). Thus both AGT (Figure 2(b)) and Ang II levels rise progressively throughout pregnancy (4). The significance of the increase in AGT in human pregnancy (70) has been underestimated despite the claim by Skinner in 1993 that ‘at all stages of pregnancy, angiotensinogen is the most important factor determining plasma renin activity and presumably Ang II production’ (69).

Native AGT is a 62 kDa protein, although it can exist in high molecular weight forms (see below). It is a serpin with the cleavage site for renin (a Val-Leu bond) in a relatively inaccessible site. Accessibility by renin to this site is improved by a redox-induced conformational change. Oxidation of the Cys 18–Cys 138 bond in AGT (89) significantly increases its renin binding affinity in the presence of the (P)RR. Oxidised AGT reacting with renin has a $K_m$ which is about 30% of reduced AGT, whilst in the presence of the (P)RR oxidised AGT has a $K_m$ only 9% that of reduced AGT. That is, oxidised AGT has a higher affinity for renin than reduced AGT and the presence of the (P)RR further enhances AGTs affinity for renin caused by oxidation of AGT. (P)RR has no effect however on the $K_m$ of the reduced AGT-renin reaction.
(\(K_m\) is 86% of that measured in the absence of (P)RR). Therefore with increasing levels of AGT in pregnancy, and the fact that the oxidised to reduced ratio has been shown to be increased in preeclampsia (89), the role of AGT has, as Skinner pointed out, been underestimated in terms of its ability to affect Ang II production. Clearly the roles of oxidised AGT and (P)RR in the aetiology of abnormal pregnancy outcomes such as preeclampsia, intrauterine growth retardation and preterm birth deserve detailed investigation. Other conformational changes in the molecular structure of AGT may also alter the kinetics of the renin-AGT reaction. For example, the Met 235 polymorphism in the AGT gene is associated with a conformational change that leads to an increased rate of formation of Ang II (89).

The molecular weight of circulating AGT can vary because it forms polymers. Monomeric AGT is a protein of 61.5 kDa or 65.5 kDa (depending on glycosylation) produced by the liver (80). Polymeric forms of AGT alter the rate of the renin-AGT reaction.

High molecular weight AGTs, which are different from those in plasma from non-pregnant women, have been found in plasma from pregnant women. Levels of high molecular weight AGT rise throughout pregnancy and are about 16% of total AGT; they increase further in pregnancy induced hypertension and hypertension that is exacerbated in pregnancy (79). The reaction of high molecular weight AGT with renin is slow (86).

High molecular weight AGTs were first described by Gordon and Sachin (20) and quantified by Tewksbury and Dart (79). Five distinct forms exist in extra fetal tissues, i.e. amnion, chorion and placenta, while only 3 forms exist in plasma (78). In plasma from pregnant women high molecular weight AGTs are polymers complexed with other proteins such as the proform of eosinophil major basic protein (proMBP), which is highly expressed in the placenta. Low levels of proMBP occur in Down’s syndrome and are also associated with poor pregnancy outcome (86). It is produced by the trophoblast placental X cells (extravillous trophoblast) (54). 2:2 polymers of proMBP/AGT and 2:2:2 of proMBP/AGT/Cd3g occur in plasma from pregnant women (55). Cd3g is complement. ProMBP and Cd3g complexes with AGT only
occur in plasma from pregnant women, although there are high molecular weight forms of AGT (140 and 100 kDa), that account for about 3 - 5% of total AGT in plasma from non pregnant subjects (46).

Therefore not only are levels of plasma AGT increased in pregnancy but AGT also influences the rate of production of Ang II depending on its redox state and the amount complexed with other proteins.

Prorenin and active renin (Figure 2(a))

In the luteal phase of the menstrual cycle, prorenin levels peak shortly after ovulation, while active renin levels rise in the mid-luteal phase (68). This suggests that ovarian prorenin is secreted at ovulation. The ovarian follicle contains renin, 99% of which is in the form of prorenin, although Ang I and Ang II are also both present, suggesting that either prorenin is nonproteolytically activated by binding to (P)RR or the very small amount of active renin, perhaps formed spontaneously, is sufficient to generate Ang I and Ang II (34).

Maternal plasma prorenin levels are at a maximum at 8-12 weeks gestation (16, 70), being about 10 times non pregnant levels at their peak (16), while active renin levels do not rise until about 20 weeks of pregnancy.

A strong correlation between serum renin levels (total) and the number of ovarian follicles was found in women in whom cycling was managed by luteinizing hormone (LH), follicle stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) (27). Ovarian prorenin is a major contributor to circulating prorenin levels in early pregnancy. Derkx et al. (16) demonstrated that in a woman with primary ovarian failure in whom embryo transfer was performed, plasma prorenin levels were only about 17% of those normally seen in early pregnancy while levels of active renin, which are secreted only by the kidney, were similar to those found in normal pregnant women. The contribution of the uteroplacental unit to the maternal circulating prorenin levels has not been demonstrated as convincingly.
Very high levels of prorenin might contribute to an increase in active renin levels, perhaps after 20 weeks gestation when the materno-placental interface is fully established. This could occur through spontaneous conversion to active renin as it is thought that there is an equilibrium between the two molecules (67). Alternatively, prorenin could interact with the 28 kDa soluble prorenin receptor thus increasing the biological activity of the circulating RAAS through two actions, exposure of the renin catalytic site as well as affecting the rate of reaction of renin with AGT.

It is surprising that despite the increased demand for retention of salt and water to compensate for the very significant increase in cardiovascular volume that occurs in pregnancy (so that it is effectively ‘under filled’) and the salt losing effects of changes in renal function (discussed below) there is not a marked increase in active renin until later in pregnancy. This emphasises the critical role of AGT in regulating plasma Ang II levels in early in gestation. This tightly controlled activity of the RAAS through the action of estrogens on AGT provides a ‘fail-safe’ mechanism that offsets the natriuretic effects of the high GFR and high levels of progesterone both of which are characteristic of normal pregnancy (1, 51). The ‘locking’ of AGT synthesis to estrogen production means that its regulation is freed from the control by complex integratory pathways and/or maternal behaviour, e.g. salt intake.

Since active renin is only secreted by the kidney, one has to conclude that the influence of AGT on plasma Ang II levels results in a negative feedback suppression to mid-luteal levels of active renin in early gestation and it is only after 20 weeks do those mechanisms that normally balance renin activity to homeostatic demand (i.e. renal sympathetic nerve activity, renal perfusion pressure and tubular flow dynamics) become significantly more influential in the control of maternal plasma renin levels.

ACE
In normal pregnancy ACE activity does not change throughout gestation (56). This may not be the case in pathological pregnancies. While we have not found any changes in ACE levels at 15 weeks gestation in women who go on to develop preeclampsia or gestational hypertension (76) pregnant diabetic rats have higher
serum ACE and lung ACE than non-diabetic control animals; as well, Ang II levels are higher (84).

ACE2
ACE2 has 40% homology with ACE. It removes a single amino acid from either Ang II to form Ang (1-7) or from Ang I to form Ang (1-9), which can subsequently be cleaved to Ang (1-7) by ACE. ACE2 is primarily localised to endothelial cells. It is upregulated in disease states such as myocardial infarction and may be shed into plasma (31). ACE2 is expressed in high amounts in early gestational placentae on the syncytiotrophoblast (59); levels of expression are lower at term. In this location placental ACE2 may cleave maternal circulating Ang II to form Ang (1-7), a vasodilator peptide which acts via the Mas R (see below). As far as we can tell ACE2 has not been measured in human plasma from pregnant women. This is because it is difficult to measure. Its catalytic activity in human plasma is inhibited. The inhibitor is a small molecular weight molecule; it is not a protein nor is it a divalent cation. Removal of the inhibitor by anion-exchange, yielded plasma ACE2 activity of 4.44 ± 0.56 pmol/ml/min in plasma from non-pregnant women (31). Be that as it may, the perfusion of maternal blood through the placenta and exposure to ACE2 in syncytiotrophoblast may reflect an important physiological site of production of Ang (1-7).

Ang Peptides (Figure 1(b))
Ang I (the decapeptide) has no known biological activity. Ang II, the octapeptide, is the most potent of the Ang peptides having 2 receptors, Ang II type 1 (AT1R) and type 2 receptors (AT2R). Additional Ang peptides resulting from the removal of N-terminal amino acids also exist in the circulation. Since biological activity depends on the phenyalanine grouping at the carboxy end, the heptapeptide, Ang III (des-aspartyl 1- Ang II) is almost as potent as Ang II. As well Ang III appears to be the preferred agonist for the AT2R in certain organs (e.g. the kidney), where its actions via the tubular AT2R, release cGMP and cause a profound natriuresis (30). The hexapeptide, Ang 3-8, (also known as Ang IV) and pentapeptide, Ang 4-8, have a similar efficacy but are weak agonists of the AT1R because of their poor affinity (15). Ang IV, however, does have a specific receptor, insulin regulated aminopeptidase (IRAP) identified by Albistion et al. (3) that is involved in cognition and memory. Ang
(1-7), formed by the action of a carboxypeptidase such as ACE2 acting on Ang II (see above) or from Ang I via other pathways acts on a very different receptor, the MasR (64).

Of these peptides, Ang II and Ang (1-7) have been most studied in human pregnancy. At 15 weeks gestation Ang II levels are lower and the Ang (1-7)/Ang II ratio higher in women carrying male fetuses than in women carrying female fetuses (75). Baker et al. (4) found that plasma Ang II levels were elevated by the second trimester. By late gestation Ang I levels were 176.4 ± 57.1 fmol/ml compared with non-pregnant levels of 32.4 ± 5.6 fmol/ml and Ang II levels were about 50% above non pregnant levels while Ang (1-7) levels were increased by about 34% (Figure 3, (5)). As explained above these high levels of Ang II and Ang (1-7) are predominately due, at least in early gestation, to the rising levels of AGT. Since ACE2 activity has not been clearly determined in normal human plasma, it is possible that the rise in Ang (1-7) represents conversion from Ang II by ACE2 at the placental interface (82, 83) but it is also possible that increased conversion of Ang II to Ang (1-7) occurs in the pregnant kidney. In Sprague-Dawley rats, Joyner et al. showed that renal levels of both ACE2 and Ang 1-7 were increased in the mid to late stages of pregnancy. Coupled with the higher renal blood flow of pregnancy, it is probable that renal ACE2 makes a significant contribution to circulating levels of Ang (1-7) in human pregnancy (28).

**Angiotensin receptors**

The roles of the circulating RAAS in human pregnancy cannot be considered in isolation from changes in the density of Ang receptors located in all those sites at which Ang peptides have biological actions. The Ang II receptors (AT₁R, AT₂R) are G-protein coupled receptors (15).

**AT₁R**

Ang II/AT₁R interactions acting via phospholipase C increase cytosolic calcium, inhibit adenyl cyclase and activate tyrosine kinases causing vasoconstriction, aldosterone synthesis and secretion and cardiac hypertrophy. Significantly, Ang II acts within the central nervous system stimulating thirst (39), vasopressin secretion (38), sympathetic nerve activity (60) and inhibiting cardiac vagal efferent nerve
traffic (36). These actions potentiate its peripheral vasoconstrictor actions on 
vascular smooth muscle so leading to increased arterial pressure. Through actions in 
the zona glomerulosa of the adrenal cortex, Ang II/AT1R stimulates aldosterone 
synthesis and secretion (72). Within the kidney, Ang II/AT1R interactions stimulate 
tubular sodium reabsorption (13). As well, Ang II acting via AT1R partially mimics 
the actions of growth factors using Ras pathways to activate mitogen activated 
protein kinases (MAPK); this action is enhanced by Ang II transactivation of growth 
factor signalling. Transactivation of epidermal growth factor (EGF) by Ang II 
stimulates MAPK and calcium dependent phosphorylation leading to activation of 
growth factor proto-oncogenes (15).

AT1R density in vascular smooth muscle taken from pregnant rats is suppressed by 
1 uM of estradiol (15). The changes in AT1R density in the maternal vasculature in 
pregnancy are unknown but Ang II binding to platelet AT1Rs from pregnant women 
has been described. Baker et al. (4) found that platelet Ang II receptors were low 
throughout pregnancy, rising at 6 weeks postpartum. Pawlak and MacDonald (57) 
showed that in non pregnant subjects there was a negative relationship between 
Ang II levels and Ang II receptors. In early pregnancy this relationship was lost 
because at this time there was a “significant reduction or nil receptor capacity but 
only a slight elevation in mean plasma angiotensin II concentration” and “this 
phenomenon of reduced or absent binding persisted into the third trimester when 
plasma angiotensin II was significantly elevated compared with all other groups”.

It is well known that vascular reactivity to Ang II is decreased both in terms of a 
reduction in pressor responses to Ang II (19) and a reduction in the reactivity of the 
maternal peripheral vasculature (35). Whether this is due to the counteracting 
effects of other vasodilator influences in pregnancy or to a reduction in AT1R is 
unknown but the fact that hand vascular reactivity of pregnant women to another 
vasoconstrictor, namely noradrenaline, was not altered but the response to Ang II 
was reduced (35), suggests that there is a reduction in AT1R vascular receptor 
density as found by others in platelets (4, 57).
Ang II acting via the AT$_2$R receptor causes vasodilation and apoptosis. In pregnancy, myometrial AT$_2$R are down regulated but in the uterine arteries of pregnant sheep a different picture is seen. Vascular AT$_2$R are upregulated by estrogens (62).

In uterine arteries from pregnant sheep, there are AT$_2$R but these are not present in uterine arteries from non-pregnant sheep (7, 41). Since Ang II/AT$_2$R interactions mediate vasodilation via nitric oxide (NO) and bradykinin, the presence of AT$_2$R in the uterine arteries could be important in offsetting the vasoconstrictor action of Ang II, so maintaining a high uteroplacental blood flow. This proposition would seem to be supported by the finding in sheep, that uteroplacental flow did not change during short-term intravenous infusions of Ang II of <60 ng/kg/min (46) or 4h infusions of 20-30 ng/kg min (74). However, when 20-30 ng/kg/min intravenous infusions of Ang II were continued for 16-24h, uteroplacental flow did decrease and the fetuses became hypoxaemic (74). 30ng/kg/min infusions of Ang II for 24 h, cause uterine arteries from pregnant sheep (studied in vitro) to contract more vigorously in response to Ang II. This was due, in part, to downregulation of AT$_2$R. Thus AT$_2$R in the pregnant uterine vasculature protect against the vasoconstrictor actions of Ang II unless high circulating levels of Ang II are sustained over many hours resulting in their downregulation (40). In addition, in female rats low doses of Ang II cause a fall in BP not seen in male rats (63). In genetically modified mice AT$_2$R null mice develop high blood pressure in third trimester (77), and AT$_2$R receptor antagonism abolishes the mid gestation decline in BP in AT$_{1a/-}$ and C57BL/6J mice (73). Thus AT$_2$R play a role in regulation of maternal blood pressure and uteroplacental flow in animal models and it is likely that AT$_2$Rs are upregulated in the systemic as well as the uteroplacental vasculature of the pregnant human.

In 2003, Santos and colleagues showed that Ang (1-7) acted via a G-protein orphan receptor, Mas (65). Ang (1-7) acting via this pathway is also vasodilator via endothelium dependant mechanisms, in particular via NO. Ang (1-7) is also anti-aquaretic and promotes thirst (29, 37), important actions of the RAAS regulation of fluid and electrolyte homeostasis in pregnancy.
Insulin regulated aminopeptidase (IRAP)

IRAP, also known as the AT₃ receptor, is the receptor for Ang IV (3). It is the same as placental oxytocinase (45). Ang IV bound to IRAP inhibits it (2). Estrogen treatment of ovariectomized ewes results in down regulation of IRAP in the outer myometrial layer (45). Whether or not the inhibitory effect of Ang IV on IRAP plays a role in parturition is unknown at this time.

Role(s) of the circulating RAAS in pregnancy

The ‘underfilled’ hypotensive cardiovascular system of pregnancy

The RAAS is activated in the 2nd half of the menstrual cycle, following ovulation. At this time, mean arterial pressure falls (from 81.7 ± 0.2 during the follicular phase to 75.4 ± 0.2 mmHg in the proliferative phase) and systemic vascular resistance is decreased (declines from 1224 ± 82 to 959 ± 59 dynes.s.cm⁻⁵, Figure 4(a)). These changes in cardiovascular function could stimulate renin release via the renal baroreceptor or increased renal sympathetic nerve activity.

As well, glomerular filtration rate is increased (from 109 ± 6 to 116 ± 7 ml.min⁻¹/1.73 m², Figure 4(b) (9)) and progesterone levels increase from 0.22 ± 0.02 to 8.13 ± 1.55 ng/ml. The rise in renin activity (0.36 ± 0.05 to 1.21 ± 0.18 ng/ml/h) and aldosterone levels (from 3.1 ± 0.3 to 8.5 ± 1.0 ng/ml, (9), Figure 5) should be seen as a compensatory response to the changes in GFR, the increased capacity of the cardiovascular compartment and to the salt losing effects of progesterone (9).

Thus late in the menstrual cycle the circulating RAAS is activated, because the fall in maternal blood pressure acting via the renal baroreceptor and sympathetic nervous system, the salt losing effects of a high GFR stimulating the macula densa and inhibition of aldosterone by progesterone, all stimulate release of renin from the kidney (in particular active renin). No further increase in active renin levels then occurs until 20 weeks gestation. The progressive rise in renin activity and Ang II prior to this time (i.e. 20 weeks) is the result of estrogen induced stimulation of AGT production (see above). The integrated pattern of changes leading to the observed alterations in the circulating RAAS in pregnancy are summarized schematically in Figures 6 and 7.
Maternal cardiovascular and renal function are profoundly altered by the presence of a conceptus. There is marked vasodilatation and an increase in blood flow particularly to the uterus, breasts, skin and kidneys, presumably in response to metabolic demand and to eliminate the waste products of metabolism. There must also be an increase in coronary blood flow to cope with the increase in cardiac output. An increase in vascular compliance occurs very early in pregnancy and threatens maintenance of blood pressure even though cardiac output is increased. The increased capacitance of the maternal circulation is due to both a reduction in systemic vascular resistance and an increase in global arterial compliance.

What causes this increase in capacitance of the maternal circulation? The following may be involved:

1) Angiogenesis and vascular remodelling;
2) Relaxin;
3) Vasodilator peptides of the RAS (e.g. Ang (1-7));
4) Downregulation of the AT1R; upregulation of AT2R
5) Vascular endothelial growth factor (VEGF), NO, Kallikrein-kinin and prostanoids.

This topic has been reviewed by Valdes et al. (83). The role of the RAS in creating the proangiogenic state of pregnancy is discussed below. Evidence for downregulation of AT1R in pregnancy has been cited above as has the vasodilator roles of Ang II or Ang III/AT2R interactions, Ang IV and Ang (1-7). These all also involve other dilator systems (e.g. NO, kallikrein-kinin system and prostacyclin) but of particular interest is the role of relaxin.

As stated above, cardiac output rises in the first trimester, mainly due to an increase in stroke volume, but systemic vascular resistance (SVR) falls to a greater extent so that by the beginning of the second trimester arterial pressure is reduced, effective renal plasma flow (ERPF) has increased by about 80% and GFR is 50% above non pregnant values (Figure 4, (1)). At the beginning of the second trimester, the decrease in systemic vascular load reaches its nadir and the increase in global arterial compliance (AC) peaks. This synergism has been proposed by Conrad to depend on the actions of the ovarian hormone, relaxin (Figure 6 and 7, (8)). Animal
studies have shown that relaxin plays a major role in pregnancy as a vasodilator, in osmoregulation and renal vasodilation (11, 12, 50). Relaxin induced increases in renal blood flow might be thought to account for pregnancy-induced increases in GFR and this seems to be the case in rodents (14). However in non-pregnant human volunteers recombinant human relaxin caused a rise in renal blood flow but this was not accompanied by an increase in GFR; thus the situation in human pregnancy seems to be more complex (71).

Conrad (12) postulates that not only is relaxin a vasodilator but acting via a relaxin receptor induces matrix metalloproteinase-2 (MMP2) which has the ability to cleave endothelin1-32 (ET1-32) from big endothelin. ET1-32 acting via ETB in endothelial cell caveolae induces nitric oxide synthase and so increases NO and vascular relaxation. This adds to the fall in renal vascular resistance and systemic vascular resistance. As well MMP-2, a gelatinase, affects the vascular extracellular matrix of small vessels leading to increases global arterial compliance (which is derived from the cardiac output and the diastolic decay of the aortic waveform (11, 12). This increase in global AC prevents excessive falls in diastolic pressure resulting from the decrease in SVR, decreases the loss of pulsatile work by the heart and contributes to the underfilling of the vascular system which together with the reduction in SVR, results in a massive demand for salt and water to fill the cardiovascular system in the face of a high GFR causing salt and water loss. The RAAS plays a pivotal role in maintaining BP and retaining salt and water under these circumstances, possibly aided by increased renal sympathetic nerve activity and early in pregnancy a lack of a rise in plasma ANP levels (Figure 8, (8)), which do not increase until 12 weeks gestation, although thereafter they are increased relative to the non pregnant state (26, 61).

The hunger for salt to maintain pregnancy and renal function (Figures 6 and 7)
No other physiological state is characterised by such intense activation of the renin-angiotensin-aldosterone system as occurs in human pregnancy. A pregnant woman requires about 500 mEq of sodium in normal pregnancy, about 20 mmol per week (21). Adequate levels of sodium are required to maintain the extracellular volume,
which includes an expanded circulating blood volume and the demands of the
captus for salt and water. For changes in these values during pregnancy see (1).
The RAAS is the mechanism that fulfills this demand for extra salt and water. The
massive increase in sodium retention is partly masked by increased water retention
because in pregnancy the threshold to vasopressin induced hyperosmotic
stimulation is reduced leading to the characteristic hyponatremic hypervolemia of
pregnancy (6).

The profound need for salt in pregnancy and the role of the RAAS system in fulfilling
that role is emphasised by studies in the Yanamamo Indians, who at the time of the
study lived on a 'no salt diet' (52). Their daily loss of sodium was about 1 mEq/day
(assuming a urinary output of about 1 L/day) and a measured urinary sodium
concentration of 1 mEq/L. When urinary aldosterone levels from pregnant
Yanamamo women were compared to their sodium excretion they were
extraordinarily high (585 ± 46 ng/ml) compared with non-pregnant (38.8 ± 31.4
ng/mL) and lactating pregnant Yanamamo women (46.2 ± 62.5 ng/mL) resulting in
only a slightly lower sodium excretion (0.7 compared with 1.4 mEq/L and 0.8
mEq/L respectively). Presumably gastrointestinal and sweat losses of sodium were
also reduced below non-pregnant levels. Levels of aldosterone were far in excess of
pregnant Guyami women who had a high salt intake (urinary sodium; 77.8 ± 30
mEq/L) and lower urinary aldosterone; 92.1 ± 119 ng/mL, (53)) even though
pregnant Guyami women also had higher urinary aldosterone levels and lower
urinary sodium levels than non-pregnant tribal women. Like urinary aldosterone,
plasma renin activity in pregnant Yanamamo women was very much greater (25.6 ±
6.4 ng/ml/h) compared with lactating and non pregnant Yanamamo women (5.0 ±
2.6 and 6.2 ± 4.1 ng/ml/h respectively) (53). Thus in Yanamamo women one can
only assume that much of the increase in renin activity is in fact due to very high
rates of secretion of renal (i.e. active renin). These data emphasise the interaction
between the demand for salt in pregnancy and the activity of the RAAS. This demand
for sodium is much greater than that of lactating women from the same tribes,
because of the large capacitance of the circulation and the high GFR characteristic of
pregnancy but not lactation. After birth, with reversion to a smaller blood volume
and lower GFR, the demand for salt is reduced; as well the concentration of sodium in breast milk is low.

Renal function in pregnancy: the intrarenal RAS and the circulating RAAS

GFR used to be described as the ‘first factor’ involved in control of sodium excretion and aldosterone as the ‘second factor’. This was based on the fact that GFR is high (about 170 L/day), so the amount of sodium filtered by the kidney is high (about 24000 mmol/day). Of that amount, 99% is reabsorbed by the renal tubules. This reabsorptive process accounts for about 90% of renal oxygen consumption, which increases in proportion to the filtered load (i.e. the amount reabsorbed) (23). Aldosterone can regulate the excretion of up to about 2% of this filtered sodium load. Progesterone is natriuretic because it is a natural antagonist of aldosterone (51).

The renal tubules also balance the amount of sodium reabsorbed to keep it in proportion to the GFR, a phenomenon known as glomerulotubular balance. Glomerulotubular balance only maintains the fraction of glomerular filtrate reabsorbed constant. Thus a rise in GFR such as occurs in pregnancy would result in an increase in the amount of sodium excreted unless there was a compensatory increase in aldosterone and Ang II mediated sodium reabsorption.

Ang II has a multiplicity of actions important for maintaining tissue perfusion. Most of these are mediated via the AT₁R. In 1950s-1960s Ang II’s role as a key regulator of aldosterone, a salt retaining hormone that acts in the distal segments of the nephron was firmly established. Its role in controlling renal salt reabsorption is however not confined to this indirect pathway. The proximal convoluted tubule reabsorbs about 65% filtered sodium load and blockade of the proximal convoluted tubule Ang II/AT₁R interaction reduces this amount (13, 22), demonstrating the key role of the intrarenal RAS described by Navar and others in sodium homeostasis (47). Ang II/AT₁R interactions also influence the activity of other sodium transporters located along the renal tubule (see (47)).
Pregnancy is a ‘proangiogenic state’- role of the RAS

It is likely that there are other actions of the maternal circulating RAAS in pregnancy. One is its role in angiogenesis. Pregnancy is a ‘proangiogenic state’. The increases in renal blood flow, the growth of the uteroplacental circulation, the marked increase in the vascularity of the mammary vascular bed and possibly changes in vascularity of other tissues in including arterial remodelling mentioned above may involve the RAS.

In certain tissues the RAS is clearly involved in angiogenesis, such as in renal development (81) and in the eye (42). Angiotensin is known to induce angiogenesis via an Ang II/AT1R interaction and we postulate it may be a key factor in placental angiogenesis (58). Angiogenesis is stimulated in human umbilical vein cells by Ang II (24). In early pregnancy, VEGF levels are increased in parallel with the increase in β-hCG levels (18). β-hCG also stimulates prorenin secretion by the ovary (27) and by placental trophoblast (17). Since the (P)RR is associated with increased VEGF levels in the eye and this effect is abolished by (P)RR blockade and by blockade of ERK1/2 signalling (87), it is tempting to suggest that the (P)RR-prorenin/renin system which is activated in early pregnancy by hCG could be involved in this early high level of production of VEGF and hence in stimulation of angiogenesis. As well aldosterone has been shown in vitro to stimulate VEGF production (85). So the rapid onset of increased tissue perfusion of the uterus, breasts skin and kidney, which must involve increased vascularity, may in part be determined by the early activation of the RAAS.

Perspectives and Significance

The activity of the circulating RAAS in pregnancy is influenced by contributions from tissue RASs (in particular the ovary), as well as the secretion of active renin by the kidney. Angiotensinogen also plays a major role. Since its production is strongly influenced by estrogens, it would seem that maintenance of fluid and electrolyte homeostasis in normal pregnancy is assured. Even so, when dietary salt intake is limited, the circulating RAAS is activated further through secretion of active renin.
Although the renin-angiotensin system is usually thought of as 'hypertensinogenic', in normal pregnancy the balance between the production of the vasodilator Ang peptide (Ang 1-7) and the vasoconstrictor peptide, Ang II is altered so that the vasopressor actions of the circulating RAS are to some extent offset (Figure 3). Furthermore under the influence of estrogens the vasodilator AT$_2$R is induced. As described above, this receptor has been shown to be important within the uteroplacental vasculature in maintenance of uteroplacental blood flow. Thus through changing activity of the various components of the circulating RAAS and its receptors, the obligatory activation of the RAAS in pregnancy which in terms of human evolution has been critical for maintenance of salt and water balance does not cause hypertension.

Despite the fact that AGT levels are 'linked' to estrogen production, overall the activity of the circulating RAAS in pregnancy is driven mainly by maternal physiological demand, so it is not surprising that its activity does not reflect the role(s) of placental and possibly other intrauterine RASs in pathological pregnancies e.g. intrauterine growth restriction (IUGR) or preeclampsia.
References


29. Joyner J, Neves LA, Stovall K, Ferrario CM, and Brosnihan KB. Angiotensin-(1-7) serves as an aquaretic by increasing water intake and diuresis in association with downregulation of aquaporin-1 during pregnancy in rats. American


Legends to Figures

Figure 1
(A) The renin-angiotensin system. (P)RR is prorenin receptor; ACE is angiotensin converting enzyme; ACE2 is a homolog of angiotensin converting enzyme; APA is aminopeptidase A; AT2R and AT1R are Ang II receptors, AT4R or IRAP is a receptor for Ang IV and MasR a receptor for Ang (1-7).
(B) Angiotensin peptides. Ang (1-7) can be produced by ACE2 actions on Ang II or Ang I.

Figure 2
(A) Plasma prorenin (solid circles) and active renin (open circles) levels throughout pregnancy (redrawn from Derkx et al., 1987 (16)).
(B) Angiotensinogen (AGT) levels throughout pregnancy. AGT levels were measured using an enzyme kinetic technique and so is a measure of the amount of AGT that renin can catalyse. Redrawn from Skinner (69). NP = non-pregnant, PP = postpartum.

Figure 3
Ang II and Ang (1-7) levels in plasma from nonpregnant (NP) and pregnant women in the third trimester. Data are reported as means ± SEM values. Redrawn from (5).

Figure 4
Changes in (A) mean arterial pressure (MAP, mmHg), cardiac output (CO, L/min) and systemic vascular resistance (SVR, torr); and (B) glomerular filtration rate (GFR, mL/min) and renal plasma flow (RPF, mL/min) in pregnancy. Measurements were made in non pregnant women and throughout pregnancy up to 36 weeks. Redrawn from (8) with correction to vertical axes.

Figure 5.
Changes in (A) plasma renin activity (PRA, ng/ml/h) and (B) plasma aldosterone levels (ALDO, ng/dL) in human pregnancy. Redrawn from (8).

Figure 6.
The actions of ovarian, placental and possibly decidual hormones directly and indirectly via their effects on maternal physiology on the circulating maternal renin-angiotensin system in human pregnancy.

Figure 7.
Effects and pathways of ovarian, placental and possibly decidual hormones on renal handling of salt in human pregnancy.

Figure 8.
Changes in (A) plasma noradrenaline (N-AD, pg/mL) and (B) atrial natriuretic factor (ANP, pg/mL) in human pregnancy. Redrawn from (8).
A

Angiotensinogen

\[ \text{Prorenin/Renin} \rightarrow \text{(P)RR} \]

\[ \text{Angiotensin I} \]

\[ \text{Angiotensin II} \]

\[ \text{Angiotensin III} \]

\[ \text{Angiotensin IV} \]

\[ \text{MasR} \]

\[ \text{AT}_{1R} \]

\[ \text{AT}_{2R} \]

\[ \text{AT}_{3R} \]

B

\[ \text{NH}_2\text{Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-Thr-Glu-COOH} \]

\[ \text{renin} \]

\[ \text{ACE} \]

\[ \text{Ang I} \]

\[ \text{NH}_2\text{Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-COOH} \]

\[ \text{ACE} \]

\[ \text{Ang II} \]

\[ \text{Aminopeptidase A} \]

\[ \text{Ang III} \]

\[ \text{NH}_2\text{Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-COOH} \]

\[ \text{Aminopeptidase B} \]

\[ \text{Ang IV} \]

\[ \text{NH}_2\text{Val-Tyr-Ile-His-Pro-Phe-COOH} \]

\[ \text{carboxypeptidase} \]

\[ \text{NH}_2\text{Asp-Arg-Val-Tyr-Ile-His-Pro-COOH} \]

\[ \text{Ang (1-7)} \]
Non-pregnant: Pregnant

Plasma Ang Peptides (fmol/mL):

Figure 3
Figure 4

A

MAP (mmHg): 60 - 80

CO (L/min): 4.5 - 8.5

SVR (torr): 1.6

GESTATION (weeks)

B

GFR (ml/min): 500 - 1100

RPF (ml/min): 100 - 200

GESTATION (weeks)
Figure 5

A

PRA (ng/mL/h)

B

ALDO (ng/dL)

GESTATION (weeks)
OVARY, PLACENTA, DECIDUA

RELAXIN

INCREASED CARDIOVASCULAR COMPLIANCE

INCREASED ESTROGENS

INCREASED AT$_2$R

VASODILATION

INCREASED CARDIOVASCULAR CAPACITANCE

LOW BP

ACTIVATION BARORECEPTORS, SNS

INCREASED PROGESTERONE

PRORENNIN and (P)RR

INCREASED AGT

INCREASED ANG II

INCREASED ANG (1-7)

INCREASED RENAL RENIN

LOW BP
OVARY, PLACENTA, DECIDUA

- INCREASED ANG II
  - INCREASED INTRARENAL RAS
  - INCREASED RENAL ANG II

- PROGESTERONE

- RELAXIN

- INCREASED RBF

- INCREASED GFR

- INCREASED SODIUM EXCRETION

- INCREASED SODIUM REABSORPTION

PLASMA VOLUME EXPANSION
Figure 8

**A**

N-AD (pg/mL)

**B**

ANP (pg/mL)

GESTATION (weeks)